explore -WSS

explore

author：fashion 2025-09-03 09:27:58 - browse：8

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： J&J to buy cancer drug developer Ambrx Biopharma

explore

WSS

'Investigate these claims': UFO transparency at center of House hearing

Democrats decry new health bill for going easy on private equity

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

Antibiotic resistance and the global rise in human conflict

Senate panel puts off hardest PBM reforms for another day

Ahead of JPM, here's who's profiting most in health care

focus

explore

Gilead needs Arcellx more than ever

explore

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Apple is now the first public company to be valued at $3 trillion

AdventHealth escalates lawsuit against insurance vendor Multiplan

ChatGPT in medicine: STAT answers readers' burning questions

UCB departs biotech trade group BIO

Hollywood unions extend contract negotiations for actors

Ahead of JPM, here's who's profiting most in health care

After affirmative action ruling, medical educators look to 'holistic review'

Democrats decry new health bill for going easy on private equity

explore

UCB departs biotech trade group BIO

Why psychiatrists like me stop taking insurance

Will the FTC rein in IQVIA's health data empire?

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Biden warns of ‘dark winter’ during final presidental debate

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

explore

explore

explore

Wikipedia